Crispr Therapeutics AG (CRSP) — Cash Flow Reinvestment Rate
Crispr Therapeutics AG (CRSP) has a Cash Flow Reinvestment Rate of 0.90x as of March 2024, reinvesting $98.52 Million (capex $721.00K plus investments $-97.80 Million) from operating cash flow of $109.75 Million. Check CRSP cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Crispr Therapeutics AG Cash Flow Reinvestment Rate (2015–2021)
Historical reinvestment intensity for Crispr Therapeutics AG across 3 annual periods. Explore CRSP strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Crispr Therapeutics AG (2015–2021)
Year-by-year capital reinvestment analysis for Crispr Therapeutics AG. For live market cap and broader valuation context, see market value of Crispr Therapeutics AG.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.92x | $1.04 Billion | $538.97 Million | $81.70 Million | ▲ +1259.5% |
| 2019 | 0.14x | $8.01 Million | $56.68 Million | $6.68 Million | ▲ +569.7% |
| 2015 | 0.02x | $1.25 Million | $59.43 Million | $1.15 Million | — |